Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 17, 2026

Coda Octopus Group Reports Fiscal First Quarter 2026 Financial Results 

View original at globenewswire.com
Coda Octopus Group Reports Fiscal First Quarter 2026 Financial Results ORLANDO, FL, March 17, 2026 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Echoscope currently accounts for approximately 80% of Marine Technology Business revenues

    60% confidence

  • Despite the uncertain global policy environment, I am pleased with our overall financial results in FQ2026 and the diversification of our revenue structure

    60% confidence

  • Company is well-positioned to capture significant value in expanding defense and underwater robotics markets with NANO GEN Series

    60% confidence

  • I am pleased with our overall results of operations in FQ2026, especially the increase in revenue by 28.8%

    60% confidence

  • All business units increased revenue in the FQ2026 period

    60% confidence

  • Fiscal year 2026 DAVD sales will be backended due to delays in defense spending appropriations and ANU assessment

    60% confidence

  • The Unmanned Underwater Vehicle market, valued at $4.8 billion in 2024, is projected to reach $11.1 billion by 2030

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Coda Octopus Group Reports Fiscal First Quarter 2026 Financial Results  — Source | Via News | Finance Via News